Drug alert for Amoxil and Augmentin
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 4 drug alert for specified batches of Amoxil (amoxicillin trihydrate; GlaxoSmithKline) vials for injection 500mg and 1g, and Augmentin (co-amoxiclav; GlaxoSmithKline) intravenous 600mg and 1.2g. This is due to a very low incidence of cracks being found in vials used for packaging of the affected products. The cracks are positioned where the base of the vial meets the side wall and there are concerns that sterility may be breached in affected vials. Further information is available from the MHRA website.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066852
Recommended from Pharmaceutical Press